Drugs / Shuxuening
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06138353 | Jan 2024 → Nov 2025 | acquired aneurysmal subarachnoid hemorrhage | Xiaolin Chen, MD | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04950790 | Apr 2018 → Dec 2021 | ischemic stroke | Peking University Third Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Shuxuening | “Shuxuening injection is developed by Shiyao Yinhu Pharmaceutical Co., Ltd., and is a sterile aqueous solution made of ginkgo biloba or ginkgo biloba extract.” NCT04950790 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04950790 ↗ |